BMS’ Krazati kneels to chemo in confirmatory colorectal cancer trial

By /

Patients treated with Bristol Myers Squibb’s Krazati in combination with cetuximab saw shorter median overall and progression-free survival than comparators on chemotherapy.

Scroll to Top